Kaori Ito

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Disease progression meta-analysis model in Alzheimer's disease
    Kaori Ito
    Pfizer Global Research and Development, New London, CT, USA
    Alzheimers Dement 6:39-53. 2010
  2. doi request reprint Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database
    Kaori Ito
    Pfizer Inc, Groton, CT 06340, USA
    J Alzheimers Dis 37:173-83. 2013
  3. doi request reprint Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database
    K Ito
    Pfizer Inc, Primary Care Business Unit, 445 Eastern Point Road, Groton, CT 06340, USA
    J Pharmacokinet Pharmacodyn 39:601-18. 2012
  4. doi request reprint Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
    Kaori Ito
    Pfizer Global Research and Development, New London, CT, USA
    Alzheimers Dement 7:151-60. 2011
  5. pmc Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory
    Kaori Ito
    Medico Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyusyu University, Fukuoka, Japan
    Br J Clin Pharmacol 63:394-403. 2007
  6. doi request reprint Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients
    Sadahiro Abe
    Clinical Pharmacology, Global Research and Development, Tokyo Laboratories, Pfizer, Tokyo, Japan
    J Clin Pharmacol 49:1071-8. 2009
  7. doi request reprint Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study
    Bharat Damle
    Pfizer Global Research and Development, Pfizer Inc, 685 Third Ave, 685 13 55, New York, NY 10017, USA
    J Clin Pharmacol 49:291-300. 2009
  8. doi request reprint Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
    James A Rogers
    Metrum Research Group, Tariffville, CT 06081, USA
    J Pharmacokinet Pharmacodyn 39:479-98. 2012
  9. doi request reprint Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change
    Wonkyung Byon
    Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    J Clin Pharmacol 50:803-15. 2010

Collaborators

Detail Information

Publications10

  1. doi request reprint Disease progression meta-analysis model in Alzheimer's disease
    Kaori Ito
    Pfizer Global Research and Development, New London, CT, USA
    Alzheimers Dement 6:39-53. 2010
    ..The model was used to estimate disease progression for both placebo-treated patients and acetylcholinesterase (AChE)-inhibitor treated patients, and factors that affected disease progression...
  2. doi request reprint Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database
    Kaori Ito
    Pfizer Inc, Groton, CT 06340, USA
    J Alzheimers Dis 37:173-83. 2013
    ..The placebo response and the underlying disease progression is difficult to differentiate in longitudinal Alzheimer's disease (AD) studies, yet it is crucial to understand for designing clinical trials and interpreting results...
  3. doi request reprint Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database
    K Ito
    Pfizer Inc, Primary Care Business Unit, 445 Eastern Point Road, Groton, CT 06340, USA
    J Pharmacokinet Pharmacodyn 39:601-18. 2012
    ..The basic method for handling boundary data used in this analysis is also applicable to handle boundary observations for numerous other endpoints...
  4. doi request reprint Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
    Kaori Ito
    Pfizer Global Research and Development, New London, CT, USA
    Alzheimers Dement 7:151-60. 2011
    ..A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Initiative...
  5. pmc Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory
    Kaori Ito
    Medico Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyusyu University, Fukuoka, Japan
    Br J Clin Pharmacol 63:394-403. 2007
    ....
  6. doi request reprint Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients
    Sadahiro Abe
    Clinical Pharmacology, Global Research and Development, Tokyo Laboratories, Pfizer, Tokyo, Japan
    J Clin Pharmacol 49:1071-8. 2009
    ..The present population PK model of linezolid described well the PK profiles in Japanese patients who have lower BW and are relatively older compared with those in the United States/European Union...
  7. doi request reprint Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study
    Bharat Damle
    Pfizer Global Research and Development, Pfizer Inc, 685 Third Ave, 685 13 55, New York, NY 10017, USA
    J Clin Pharmacol 49:291-300. 2009
    ..At clinically relevant, doses nelfinavir is unlikely to cause QTc prolongation...
  8. doi request reprint Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
    James A Rogers
    Metrum Research Group, Tariffville, CT 06081, USA
    J Pharmacokinet Pharmacodyn 39:479-98. 2012
    ..A further advantage of the BR model is that it constrains values to the range of the original instrument for simulation purposes, in contrast to methodologies that provide appropriate constraints only for conditional expectations...
  9. doi request reprint Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change
    Wonkyung Byon
    Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    J Clin Pharmacol 50:803-15. 2010
    ..The analyses support the recommended dose of pregabalin in patients with fibromyalgia of 300 to 450 mg/d...